A 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both present: X-34 plaque area differed across IgG1, lecanemab, and Fc-silenced LALA-PG groups (P = 0.0003), 82E1 plaque area differed across groups (P < 0.0001), and microglia-deficient mice showed …
A 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sessions in 72.7% of patients, while 27.3% stopped esketamine because the flashbacks persisted.1 Research Highlights Flashbacks usually faded, but not always: In 16 of 22 patients (72.7%), esketamine-related trauma re-experiencing disappeared …
A 2026 eLife study recorded 3,881 lateral orbitofrontal cortex units in rats and found that prior cocaine use made the OFC over-distinguish task positions that controls treated as functionally equivalent. The headline result was not gross task failure: cocaine-experienced rats still performed the odor task, but their OFC ensembles showed higher S1-vs.-S2 decoding than sucrose …
A 2026 case report linked 1 mg nightly guanfacine modified-release to first-ever cessation of intrusive deliberate self-harm thoughts in a 16-year-old with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) traits, borderline personality disorder (BPD) traits, and post-traumatic stress disorder (PTSD). The same case became more interesting after the patient stopped taking guanfacine and the self-harm …
Parenteral clomipramine has a strong clinical myth around it: bypass the gut, raise parent-drug exposure quickly, and maybe accelerate rescue in severe depression or OCD. A 2026 systematic review found the route advantage was not clearly proven: in depression, 5 RCTs without high risk of bias did not show clear IV or IM superiority over …
A 2026 male-mouse study found that 30 mg/kg dexamethasone for 5 days increased light-phase wakefulness (t13 = 4.122, p = 0.0012), decreased NREM sleep (t13 = 4.412, p = 0.0007), and amplified orexin-neuron activity during NREM-to-wake transitions (F1,9 = 6.941, p = 0.0272). The result points to orexin-linked hyperarousal as a testable explanation for steroid-induced …
A 60-patient randomized trial of lithium loading for acute bipolar I mania reported faster serum lithium attainment than standard titration and a larger 14-day Young Mania Rating Scale (YMRS) change score, but the same accepted manuscript says absolute YMRS scores at Days 3, 7, and 14 were not significantly different between the 2 arms when …